Comparison of blinatumomab and CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis

References

• Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014 Dec 20;32(36):4134–4140. doi: 10.1200/JCO.2014.56.3247
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012 Sep 6;120(10):2032–41. doi: 10.1182/blood-2011-12-399287
   PubMed Web of Science ®Google Scholar
• Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood. 2020;136(16):1803–1812. doi: 10.1182/blood.2019004043
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011 May 15;317(9):1255–60.
   PubMed Web of Science ®Google Scholar
• Cao J, Wang G, Cheng H, et al. Potent anti-leukemia activities of humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2018 Jul;93(7):851–858.
   PubMed Web of Science ®Google Scholar
• Slaney CY, Wang P, Darcy PK, et al. Cars versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment. Cancer Discovery. 2018 Aug;8(8):924–934.
   PubMed Web of Science ®Google Scholar
• Frey NV, Shaw PA, Hexner EO, et al. Optimizing chimeric antigen receptor T-Cell therapy for adults with acute lymphoblastic leukemia. J Clin Oncol. 2020 Feb 10;38(5):415–422. doi: 10.1200/JCO.19.01892
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Higgins JP, Altman DG, et al. Analysing data and undertaking meta‐analyses. In: Higgins JPT, Thomas J, Chandler J, et al., editors. Cochrane handbook for systematic reviews of interventions; 2019. doi: 10.1002/9781119536604.ch10
   Google Scholar
• Deeks JJ, Altman DG, Bradburn MJ. Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis. In: Egger M, Smith GD, Altman DG, editors. Systematic Reviews in Health Care; 2001. doi: 10.1002/9780470693926.ch15
   Google Scholar
• Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017 Mar 2;376(9):836–847. doi: 10.1056/NEJMoa1609783
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Oh I, Miyamoto T, et al. Efficacy and safety of blinatumomab: post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Asia-Pac J Clin Oncol. 2022 Jun 29;18(3):311–318. doi: 10.1111/ajco.13609
   PubMed Web of Science ®Google Scholar
• Stein AS, Kantarjian H, Gökbuget N, et al. Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 Aug;25(8):1498–1504.
   PubMed Web of Science ®Google Scholar
• Dombret H, Topp MS, Schuh AC, et al. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2019 Sep;60(9):2214–2222.
   PubMed Web of Science ®Google Scholar
• Jung SH, Lee SR, Yang DH, et al. Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. Ann Hematol. 2019 Jan;98(1):151–158.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Zugmaier G, et al. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Cancer. 2021 Feb 15;127(4):554–559. doi: 10.1002/cncr.33298
   PubMed Web of Science ®Google Scholar
• von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/Phase II study of Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016 Dec 20;34(36):4381–4389. doi: 10.1200/JCO.2016.67.3301
   PubMed Web of Science ®Google Scholar
• Locatelli F, Zugmaier G, Mergen N, et al. Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J. 2020 Jul 24;10(7):77. doi: 10.1038/s41408-020-00342-x
   PubMed Web of Science ®Google Scholar
• Salhotra A, Yang D, Mokhtari S, et al. Outcomes of allogeneic hematopoietic cell transplantation after salvage therapy with Blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2020 Jun;26(6):1084–1090.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Min GJ, Park SS, et al. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer Med. 2019 Dec;8(18):7650–7659.
   PubMed Web of Science ®Google Scholar
• Jabbour EJ, Gökbuget N, Kantarjian HM, et al. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 2019 Dec 1;125(23):4181–4192. doi: 10.1002/cncr.32335
   PubMed Web of Science ®Google Scholar
• Badar T, Szabo A, Litzow M, et al. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplant. 2021 Aug;56(8):1998–2004.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507–17. doi: 10.1056/NEJMoa1407222
   PubMed Web of Science ®Google Scholar
• Xiao L, Huang H, Huang X, et al. Efficacy of anti-CD19 chimeric antigen receptor modified T (CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial. Am Soc Clin Oncol. 2017;35(15_suppl):7028–7028. doi: 10.1200/JCO.2017.35.15_suppl.7028
   Google Scholar
• Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021 Aug 7;398(10299):491–502. doi: 10.1016/S0140-6736(21)01222-8
   PubMed Web of Science ®Google Scholar
• Hay KA, Gauthier J, Hirayama AV, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019 Apr 11;133(15):1652–1663. doi: 10.1182/blood-2018-11-883710
   PubMed Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018 Feb 1;378(5):449–459. doi: 10.1056/NEJMoa1709919
   PubMed Web of Science ®Google Scholar
• Deng B, Chang AH, Yang J, et al. Safety and efficacy of low dose CD19 targeted chimeric antigen receptor T (CAR-T) cell immunotherapy in 47 cases with relapsed refractory B-cell acute lymphoblastic leukemia (B-ALL). Blood. 2016;128(22):649. doi: 10.1182/blood.V128.22.649.649
   Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448. doi: 10.1056/NEJMoa1709866
   PubMed Web of Science ®Google Scholar
• Li L, Liu J, Xu M, et al. Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients. Cell Death Dis. 2020;11(3):1–13. doi: 10.1038/s41419-020-2388-1
   PubMed Web of Science ®Google Scholar
• Pasquini MC, Hu ZH, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 Nov 10;4(21):5414–5424. doi: 10.1182/bloodadvances.2020003092
   PubMed Web of Science ®Google Scholar
• Zhang X, Lu XA, Yang J, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020 May 26;4(10):2325–2338. doi: 10.1182/bloodadvances.2020001466
   PubMed Web of Science ®Google Scholar
• Jiang H, Li C, Yin P, et al. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial. Am J Hematol. 2019 Oct;94(10):1113–1122.
   PubMed Web of Science ®Google Scholar
• Zhao YL, Liu DY, Sun RJ, et al. Integrating CAR T-Cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-Cell or chemotherapy-based complete remission in B-Cell acute lymphoblastic leukemia. Front Immunol. 2021;12:605766. doi: 10.3389/fimmu.2021.605766
   PubMedGoogle Scholar
• Verneris MR, Ma Q, Zhang J, et al. Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2021 Dec 14;5(23):5387–5395. doi: 10.1182/bloodadvances.2020004045
   PubMed Web of Science ®Google Scholar
• Myers RM, Taraseviciute A, Steinberg SM, et al. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol. 2022 Mar 20;40(9):932–944. doi: 10.1200/JCO.21.01405
   PubMed Web of Science ®Google Scholar
• Stein A, Franklin JL, Chia VM, et al. Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Drug Saf. 2019;42(5):587–601. doi: 10.1007/s40264-018-0760-1
   PubMed Web of Science ®Google Scholar
• Brandl C, Haas C, d’Argouges S, et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother. 2007 Oct;56(10):1551–1563.
   PubMed Web of Science ®Google Scholar